Komo: Maintaining Kingsley Biotech's (01548) “Gain” Rating Target Price of HK$41

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that J.P. Morgan Chase released a research report saying that Lilly (LLY.US) announced that it had reached TuneLab cooperation agreements with Kingsley Biotech (01548) and others, and that the bank maintained Kingsley's “increase” rating and target price of HK$41. Among them, Kingsley will provide wet laboratory services to TuneLab member companies, including gene synthesis, protein expression, purification, and testing according to standardized protocols to help transform drug candidates generated by artificial intelligence into experimental results. The bank believes it will help strengthen Kingsley's leading position in the AI-driven drug discovery (AIDD) ecosystem.